These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 11862177)

  • 1. Stromelysin 3 expression: a useful marker for the differential diagnosis dermatofibroma versus dermatofibrosarcoma protuberans.
    Cribier B; Noacco G; Peltre B; Grosshans E
    J Am Acad Dermatol; 2002 Mar; 46(3):408-13. PubMed ID: 11862177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stromelysin-3 expression in the differential diagnosis of dermatofibroma and dermatofibrosarcoma protuberans: comparison with factor XIIIa and CD34.
    Kim HJ; Lee JY; Kim SH; Seo YJ; Lee JH; Park JK; Kim MH; Cinn YW; Cho KH; Yoon TY
    Br J Dermatol; 2007 Aug; 157(2):319-24. PubMed ID: 17596171
    [TBL] [Abstract][Full Text] [Related]  

  • 3. D2-40, a novel immunohistochemical marker in differentiating dermatofibroma from dermatofibrosarcoma protuberans.
    Bandarchi B; Ma L; Marginean C; Hafezi S; Zubovits J; Rasty G
    Mod Pathol; 2010 Mar; 23(3):434-8. PubMed ID: 20062007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apolipoprotein D in CD34-positive and CD34-negative cutaneous neoplasms: a useful marker in differentiating superficial acral fibromyxoma from dermatofibrosarcoma protuberans.
    Lisovsky M; Hoang MP; Dresser KA; Kapur P; Bhawan J; Mahalingam M
    Mod Pathol; 2008 Jan; 21(1):31-8. PubMed ID: 17885669
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of CD163 in dermatofibroma, cellular fibrous histiocytoma, and dermatofibrosarcoma protuberans: comparison with CD68, CD34, and Factor XIIIa.
    Sachdev R; Sundram U
    J Cutan Pathol; 2006 May; 33(5):353-60. PubMed ID: 16640542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High proliferative activity excludes dermatofibroma: report of the utility of MIB-1 in the differential diagnosis of selected fibrohistiocytic tumors.
    Hanly AJ; Jordà M; Elgart GW; Badiavas E; Nassiri M; Nadji M
    Arch Pathol Lab Med; 2006 Jun; 130(6):831-4. PubMed ID: 16740036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Possible contribution of PDGF-BB-induced autophagy in dermatofibrosarcoma protuberans: Autophagy marker Atg5 could be a differential marker between dermatofibrosarcoma protuberans and dermatofibroma.
    Motegi SI; Fujiwara C; Sekiguchi A; Yamazaki S; Yokoyama Y; Yasuda M; Ishikawa O
    J Dermatol Sci; 2019 Feb; 93(2):139-141. PubMed ID: 30704939
    [No Abstract]   [Full Text] [Related]  

  • 8. LN-2 (CD74). A marker to distinguish atypical fibroxanthoma from malignant fibrous histiocytoma.
    Lazova R; Moynes R; May D; Scott G
    Cancer; 1997 Jun; 79(11):2115-24. PubMed ID: 9179057
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD99 expression in dermatofibrosarcoma protuberans and dermatofibroma.
    Kazlouskaya V; Malhotra S; Kabigting FD; Lal K; Elston DM
    Am J Dermatopathol; 2014 May; 36(5):392-6. PubMed ID: 24247571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phosphohistone-H3 and Ki67: Useful Markers in Differentiating Dermatofibroma From Dermatofibrosarcoma Protuberans and Atypical Fibrohistiocytic Lesions.
    Agarwal A; Gopinath A; Tetzlaff MT; Prieto VG
    Am J Dermatopathol; 2017 Jul; 39(7):504-507. PubMed ID: 28609344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of stromelysin 3 in basal cell carcinomas.
    Cribier B; Noacco G; Peltre B; Grosshans E
    Eur J Dermatol; 2001; 11(6):530-3. PubMed ID: 11701402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunohistochemical markers in fibrohistiocytic lesions: factor XIIIa, CD34, S-100 and p75.
    West KL; Cardona DM; Su Z; Puri PK
    Am J Dermatopathol; 2014 May; 36(5):414-9. PubMed ID: 24162384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Role of CD34 and D2-40 in the Differentiation of Dermatofibroma and Dermatofibrosarcoma Protuberans.
    Sadullahoğlu C; Dere Y; Atasever TR; Öztop MT; Karaaslan Ö
    Turk Patoloji Derg; 2017; 1(1):223-227. PubMed ID: 28832078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Collagen triple helix repeat containing-1 in the differential diagnosis of dermatofibrosarcoma protuberans and dermatofibroma.
    Wang L; Xiang YN; Zhang YH; Tu YT; Chen HX
    Br J Dermatol; 2011 Jan; 164(1):135-40. PubMed ID: 20849518
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Connexin 43 in Dermatofibroma and Dermatofibrosarcoma Protuberans: Diagnostic, Pathogenic, and Therapeutic Implications.
    Fernandez-Flores A; Varela-Vazquez A; Mayan MD; Fonseca E
    Am J Dermatopathol; 2023 Dec; 45(12):812-815. PubMed ID: 37982464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The pathological distinction between "deep penetrating" dermatofibroma and dermatofibrosarcoma protuberans.
    Wick MR; Ritter JH; Lind AC; Swanson PE
    Semin Cutan Med Surg; 1999 Mar; 18(1):91-8. PubMed ID: 10188848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atrophic variants of dermatofibroma and dermatofibrosarcoma protuberans.
    Zelger BW; Ofner D; Zelger BG
    Histopathology; 1995 Jun; 26(6):519-27. PubMed ID: 7545142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sclerosing Dermatofibrosarcoma Protuberans Shows Significant Overlap With Sclerotic Fibroma in Both Routine and Immunohistochemical Analysis: A Potential Diagnostic Pitfall.
    Abdaljaleel MY; North JP
    Am J Dermatopathol; 2017 Feb; 39(2):83-88. PubMed ID: 28134725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stromelysin-3 mRNA associated with myofibroblasts is overexpressed in aggressive basal cell carcinoma and in dermatofibroma but not in dermatofibrosarcoma.
    Undén AB; Sandstedt B; Bruce K; Hedblad M; Stahle-Bäckdahl M
    J Invest Dermatol; 1996 Aug; 107(2):147-53. PubMed ID: 8757754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. When Immunohistochemistry Deceives Us: The Pitfalls of CD34 and Factor XIIIa Stains in Dermatofibroma and Dermatofibrosarcoma Protuberans.
    John AM; Holahan HH; Singh P; Handler MZ; Lambert WC
    Skinmed; 2017; 15(1):53-55. PubMed ID: 28270311
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.